Madoka Mori‐Yoshimura

Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial

Michael G. Hanna, Umesh A. Badrising, Olivier Benvéniste et al. · The Lancet Neurology · 2019 · 128 citations · Full text

Autoimmune Disease, Immunology, Placebo-controlled Phase 2B +4

Muscle MRI in patients with dysferlinopathy: pattern recognition and implications for clinical trials

Jordi Díaz‐Manera, Roberto Fernández‐Torrón, Jaume Llauger et al. · Journal of Neurology Neurosurgery & Psychiatry · 2018 · 111 citations · Full text

The Clinical Outcome Study for dysferlinopathy

Elizabeth Harris, Catherine L. Bladen, Anna Mayhew et al. · Neurology Genetics · 2016 · 108 citations · Full text

Pediatric necrotizing myopathy associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies

Wen‐Chen Liang, Akinori Uruha, Shigeaki Suzuki et al. · Lara D. Veeken · 2016 · 88 citations · Full text

Rheumatology, Autoimmune Disease, Childhood Arthritis +13

Characteristics of Japanese Duchenne and Becker muscular dystrophy patients in a novel Japanese national registry of muscular dystrophy (Remudy)

Harumasa Nakamura, En Kimura, Madoka Mori‐Yoshimura et al. · Orphanet Journal of Rare Diseases · 2013 · 73 citations · Full text